- Tevogen Bio (TVGN) advances cytotoxic T lymphocyte (CTL) therapy against EBV-associated lymphomas.
- Proprietary ExacTcell™ technology and Tevogen.AI enhance peptide identification.
- Program remains in preclinical evaluation phase with ongoing confirmation studies.
Tevogen Bio (TVGN) has announced significant progress in the development of a cytotoxic T lymphocyte (CTL) therapy specifically targeting Epstein-Barr virus (EBV)-associated lymphomas. The development process is leveraging the company’s proprietary ExacTcell™ technology, along with artificial intelligence (AI) provided by Tevogen.AI, to identify and validate EBV peptides for potential clinical trials.
The research and development team is actively conducting confirmation studies on CTL responses to selected viral peptides. AI is being used to expedite the identification of immunologically active targets across the EBV genome, which is expected to fortify the therapeutic precision of the treatment.
Chief Scientific Officer Neal Flomenberg has highlighted this targeted approach as a promising research direction for treating EBV-driven cancers. Tevogen Bio is currently in the preclinical evaluation phase and intends to provide further updates as the research moves forward.
